Recce Pharmaceuticals

Recce Pharmaceuticals FCF Growth

The Year-over-Year Free Cash Flow Growth of Recce Pharmaceuticals (RCE.AX) as of Nov 22, 2026 is 51.37 %. In the previous year, Year-over-Year Free Cash Flow Growth was -55.65 % — a change of -192.32% (higher).

FCF Growth

51.37 %

YoY

-192.32%

Last updated:

Year-over-Year Free Cash Flow Growth of Recce Pharmaceuticals is 2026 51.37 % . Year-over-Year Free Cash Flow Growth of Recce Pharmaceuticals was 2025 -55.65 % . It decreases by -192.32% higher compared to the previous year.

The Recce Pharmaceuticals FCF Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Growth
Date
FCF Growth
Jan 1, 2019
-41.46 AUD
Jan 1, 2020
-41.13 AUD
Jan 1, 2021
-108.00 AUD
Jan 1, 2022
-14.10 AUD
Jan 1, 2023
-40.61 AUD
Jan 1, 2024
-3.34 AUD
Jan 1, 2025
-55.65 AUD
Jan 1, 2026
51.37 AUD
The Recce Pharmaceuticals FCF Growth history
YEARFCF GrowthYoY
51.37 %-192.32%
-55.65 %+1,568.04%
-3.34 %-91.78%
-40.61 %+187.92%
-14.10 %-86.94%
-108.00 %+162.59%
-41.13 %-0.81%
-41.46 %-236.44%
30.39 %-148.41%
-62.78 %-84.64%
-408.67 %-68.35%
-1,291.21 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Recce Pharmaceuticals Stock analysis

What does Recce Pharmaceuticals do? Recce Pharmaceuticals Ltd. develops pharmaceutical drugs targeting germ-killing therapies, focusing on anti-infective solutions. The company’s pipeline includes RECCE 327, an intravenous and topical therapy for serious bacterial infections including superbugs, RECCE 435 as an oral treatment for bacterial infections, and RECCE 529 for viral infections. All compounds are 100% water soluble across all pH levels in liquid form, leveraging multi-layered mechanisms to combat bacterial and viral mutations. The company operates through research and development, with no additional product lines or services mentioned. Recce Pharmaceuticals Ltd. generates revenue primarily through the development and potential commercialization of its anti-infective drugs. The target market includes healthcare providers and institutions treating serious infections, particularly those dealing with antibiotic-resistant bacteria and viral pathogens. The company’s focus on broad-spectrum synthetic polymer anti-infectives positions it for partnerships with pharmaceutical distributors and healthcare systems seeking novel treatments for life-threatening infections. The business model relies on the progression of its drug pipeline from research to clinical trials and eventual market entry. RECCE 327, RECCE 435, and RECCE 529 are the only products described, with no mention of licensing agreements, partnerships, or additional revenue streams beyond drug development and sales. The company’s financial success depends on the successful advancement of these compounds through regulatory approval processes. Recce Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Recce Pharmaceuticals stock

Year-over-Year Free Cash Flow Growth of Recce Pharmaceuticals is 51.37 % in 2026.

On Eulerpool you can find the complete historical development of Year-over-Year Free Cash Flow Growth Recce Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

FCF growth measures the percentage change in free cash flow. Growing FCF indicates improving cash generation capability.

To evaluate Year-over-Year Free Cash Flow Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Free Cash Flow Growth.

Year-over-Year Free Cash Flow Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Free Cash Flow Growth's Recce Pharmaceuticals historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Recce Pharmaceuticals

All Key Metrics — Recce Pharmaceuticals